Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes

NCT00518882 · Completed

Last updated 2026-05-28

This clinical trial tested whether adding the medications liraglutide or exenatide to the current treatment of adults with type 2 diabetes improved blood sugar control over 26 weeks.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 467 people

Who can join Ages 18–80 · all sexes

Timeline Started 2007-08 · est. completion 2009-04

Where 125 sites · Austria, Denmark, Finland, France, Germany, Ireland, North Macedonia, Norway, Poland, Puerto Rico, Romania, Slovenia, Spain, Sweden, Switzerland, United States

What this study is testing ClinicalTrials.gov NCT00518882 ↗

Description as written by the study sponsor.

This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to compare the effect on glycaemic control of liraglutide or exenatide when added to subject's ongoing OAD (oral anti-diabetic drug) treatment of either metformin, sulphonylurea or a combination of both in subjects with type 2 diabetes. Two trial periods: A 26 week randomised, followed by a 52 week extension (14 + 38 weeks) where all subjects received liraglutide + OAD after previous randomisation to either liraglutide or exenatide, both combined with OAD treatment.

Treatments tested

liraglutide Drug

1.8 mg once daily for s.c. (under the skin) injection.
exenatide Drug

10 mcg twice daily for s.c. (under the skin) injection.

Main thing measured	Change in Glycosylated A1c (HbA1c) at Week 26
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Diabetes Mellitus, Type 2
GLP-1 drugs	liraglutide, exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00518882 ↗